Temsirolimus
- TRADE NAME: Torisel (Wyeth)
- INDICATIONS: Renal cell carcinoma, other cancers
- CLASS: Analog of sirolimus, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), mTOR inhibitor
- HALF-LIFE: 17 hours
ACE inhibitors, Atazanavir, BCG Vaccine, Benazepril, Captopril, Carbamazepine, Clarithromycin, Clozapine, Conivaptan, Cyclosporine, Darunavir, Dasatinib, Denosumab, Dexamethasone, Digoxin, Enalapril, Fluconazole, Fosinopril, Grapefruit Juice, Hypoglycemic agents, Indinavir, Itraconazole, Ketoconazole, Leflunomide, Lisinopril, Live and inactive vaccines, Macolide antibiotics, Natalizumab, Nefazodone, Nelfinavir, P-glycoprotein inhibitors, Phenobarbital, Phenytoin, Pimecrolimus, Posaconazole, Protease inhibitors, Quinapril, Ramipril, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Sunitinib, Tacrolimus, Telithromycin, Tipranavir, Trastuzumab, Voriconazole
PREGNANCY CATEGORY: D
Contra-indicated in patients with bilirubin >1.5xULN.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of temsirolimus in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
